TELA Bio, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-38.8M | $-37.8M | $-46.7M | $-44.3M | $-33.3M | $-28.8M | $-22.4M | $-21.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $630.0K | $632.0K | $428.0K | $383.0K | $231.0K | $221.0K | $278.0K | $463.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.8M | $4.4M | $5.0M | $4.0M | $3.7M | $2.1M | $457.0K | $216.0K |
| Net Cash from Operating Activities | $-28.2M | $-41.6M | $-40.9M | $-40.7M | $-30.4M | $-24.5M | $-25.5M | $-19.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $448.0K | $989.0K | $611.0K | $872.0K | $627.0K | $167.0K | $197.0K | $62.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $846.0K | $4.5M | $-599.0K | $-1.9M | $-627.0K | $9.1M | $-12.0M | $-1.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $25.8M | $43.1M | $46.3M | $40.9M | $585.0K | $44.4M | $65.5M | $27.4M |
| Net Change in Cash | $-1.8M | $5.9M | $5.0M | $-1.9M | $-30.5M | $29.1M | $28.0M | $5.9M |
| Free Cash Flow | $-28.7M | $-42.6M | $-41.5M | $-41.6M | $-31.1M | $-24.6M | $-25.7M | $-20.0M |